Heel R C, Brogden R N, Pakes G E, Speight T M, Avery G S
Drugs. 1980 Mar;19(3):161-80. doi: 10.2165/00003495-198019030-00001.
Colestipol is an anion exchange resin with bile acid sequestering properties resembling those of cholestyramine, another lipid-lowering binding resin. In daily doses of 15 to 30g colestipol reduces total plasma cholesterol concentrations (primarily low density lipoprotein cholesterol) by about 15 to 30%, but plasma triglyceride concentrations may be unchanged or in some patients increased. Thus, like cholestyramine, colestipol is of benefit in patients with primary hypercholesterolaemia without associated hypertriglyceridaemia (type IIa hyperlipoproteinaemia). Colestipol is odourless and tasteless, and is said by some to be more readily tolerated by patients than cholestyramine, leading to improved compliance, but such data has not been documented in most studies. Side effects of colestipol treatment are primarily gastrointestinal in nature since the drug is essentially unabsorbed. As with cholestyramine, colestipol may bind with other concomitantly administered drugs reducing their absorption or enterohepatic recirculation; dosage intervals of other concurrent medications should be adjusted to minimise the potential for such an interaction.
考来替泊是一种阴离子交换树脂，具有与另一种降脂结合树脂考来烯胺相似的胆汁酸螯合特性。每日服用15至30克考来替泊可使血浆总胆固醇浓度（主要是低密度脂蛋白胆固醇）降低约15%至30%，但血浆甘油三酯浓度可能保持不变，或在某些患者中升高。因此，与考来烯胺一样，考来替泊对无相关高甘油三酯血症的原发性高胆固醇血症患者（IIa型高脂蛋白血症）有益。考来替泊无味无臭，有人认为患者对其耐受性比考来烯胺更好，从而提高了依从性，但大多数研究中尚未记录此类数据。考来替泊治疗的副作用主要是胃肠道方面的，因为该药物基本不被吸收。与考来烯胺一样，考来替泊可能与其他同时服用的药物结合，减少它们的吸收或肠肝循环；应调整其他同时服用药物的给药间隔，以尽量减少这种相互作用的可能性。
